Cytovia has been built through multiple collaborations with academic researchers, leading medical centers, and strategic partners. We aim to accelerate the transformation of cancer therapy and develop first-in-class products in areas of major unmet medical need.

 

As Cytovia matures its gene-edited iNK/CAR-iNK and Flex-NK™ bispecific antibody platforms, we are open to research partnerships and co-development with academic institutions and industry partners to broaden the use of NK Cell Therapies.